JPRN-UMIN000046138
Completed
Phase 2
A pilot single-arm study of the effects of remote cognitive behavioral therapy on somatic symptoms - A pilot single-arm study of the effects of remote cognitive behavioral therapy on somatic symptoms
Graduate School of Medicine Chiba University Department of Cognitive Behavioral Physiology0 sites12 target enrollmentNovember 25, 2021
Conditionssomatic symptoms
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- somatic symptoms
- Sponsor
- Graduate School of Medicine Chiba University Department of Cognitive Behavioral Physiology
- Enrollment
- 12
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Patients who are complicated by serious mental disorders such as DSM\-5 neurocognitive disorder group, psychotic disorder, bipolar disorder, or substance\-related disorder, and who are expected to discontinue cognitive behavioral therapy due to worsening of these symptoms. (2\) Patients with mental retardation (referring to assessment scores such as JART\-25: Japanese Adult Reading Test\-25\) or autism spectrum disorder (referring to AQ: Autism Spectrum Index, etc.). (3\) Those who have a serious progressive physical disease that is expected to interrupt the study. (4\) Patients who are judged by the principal investigator or the study psychologist to be inappropriate for the safe conduct of the study. (5\) Persons whose physical symptoms involve litigation or compensation. Translated with www.DeepL.com/Translator (free version)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Investigating the impact of the empowerment program on psoriasis patientsIRCT20230219057453N1Tehran University of Medical Sciences52
Active, not recruiting
Phase 1
Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosuPyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising.MedDRA version: 20.0Level: PTClassification code 10037635Term: Pyoderma gangrenosumSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-000762-65-DETechnische Universität München, School of Medicine, represented by Dean7
Recruiting
Not Applicable
Remote ischemic preconditioning and paiRemote ischemic preconditioningPainQST (Quantitative Sensory Testing)Geisoleerde ischemische behandelingPijnQST (kwantitatieve sensorische testen)NL-OMON23701drs. V.D. LinssenUniversitair Medisch Centrum RadboudumcAfdeling AnesthesiologiePhilips van Leydenlaan 256525 EX NijmegenPostbus91016500 HB NijmegenNederland Telefoon(024) 36 55653E-mailvera.linssen@radboudumc.nl12
Active, not recruiting
Not Applicable
The Australian CareLink Quality and Impact of Remote Follow-Up Evaluation Study (The ACQUIRE Study); to assess time and financial burden for device follow-up in patients with a pacemaker, implantable cardioverter defibrillator or cardiac resynchronisation therapy device.Remote monitoring of implanted cardiac devices: Pacemaker, Implantable Cardioverter Defibrillator (ICD) or cardiac resynchronisation therapy (CRT) deviceCardiovascular - Other cardiovascular diseasesACTRN12607000517471Medtronic Australasia Pty Ltd225
Not yet recruiting
Phase 3
Ayurvedic management of Kaphaja Unmada (Depressive disorders)CTRI/2024/07/070417Post Graduate Institute of Ayurved Jodhpur